Recent Company News

• 09:44 PM ET Sep 22, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 10:03 PM ET Oct 16, 2025
  

  Clinuvel Pharmaceuticals receives first strike on remuneration report, as shareholders vote 63.0% against (A$11.70, -0.29)

• 08:35 AM ET Oct 16, 2025
  

  StreetAccount European Reads

• 09:50 PM ET Oct 15, 2025
  

  Clinuvel Pharmaceuticals notes Health Canada requests additional time for review of SCENESSE in EPP; review extended to 2026 (A$12.01, +0.20)

• 06:35 PM ET Sep 30, 2025
  

  Clinuvel Pharmaceuticals MD Philippe Wolgen has resumed his duties as CEO (A$11.80, 0.00)

• 06:44 PM ET Sep 28, 2025
  

  Clinuvel Pharmaceuticals to advance new sustained-release liquid drug formulations in preclinical program; first formulations expected to complete in 2H26 (A$11.30, 0.00)

• 06:37 PM ET Sep 22, 2025
  

  EMA to amend label for Clinuvel's SCENESSE (afamelanotide) enabling adult erythropoietic protoporphyria patients to receive treatment every two months (A$11.22, 0.00)

• 06:32 PM ET Sep 18, 2025
  

  Clinuvel Pharmaceuticals presents new patient cases demonstrating efficacy of SCENESSE in vitiligo patients at EADV conference (A$11.52, 0.00)